Join the Conversation with ATA's Special Interest Groups

Special Interest Groups provide ATA members with exclusive access to in-depth discussions, information sharing, strategic brainstorming, and collaboration with peers, policy-makers, practitioners and administrators. SIGs work to address critical issues, promote and support telehealth within their specialty, provide authoritative guidance and information to the broader ATA community, and sponsor various activities throughout the year.

Join the conversation! Click on a group to learn more about its focus and leadership. See upcoming meetings.

Question about how to join a meeting? Checkout our Communities FAQ page.

Member only content

Decentralized Clinical Trials

4th Mondays, 3 pm EDT
58 Members
Last Activity: August 22, 2022
Decentralized Clinical Trials (DCT) and hybrid trials are becoming more of a norm given the impact of the COVID-19 pandemic. By creating more patient-centered clinical trials, a decentralized approach can enhance pharma research by attracting a more diverse patient population and eliminating existing barriers to participating in research studies, including COVID-related limitations. Telehealth and remote patient monitoring (RPM) will play an important role in advancing decentralized technology-driven trials. To address this important opportunity to enable equal access to clinical trials by leveraging telehealth and virtual care technologies, the ATA has convened a member special interest group (SIG). The goals of the group include: 1. Pursue policy/advocacy to remove barriers to allow interstate work and other legislation 2. Create practice guidelines to leverage existing telehealth and RPM solutions 3. Address issues of data flow, a subset of our work on telehealth interoperability The new SIG has convened three subgroups to help achieve these goals in actionable increments, including partnership opportunities: · Policy/Advocacy o Identify the best entity to create and maintain a registry of state laws that impact conduct of DCTs o Evaluate Drug Safety & Quality Act of 2013 for any barriers to implementation of DCTs · Best Practices o Leverage existing and create new content to help research sites understand what they need to do to participate in DCTs · Data Flows o Inventory existing standards impacting DCTs o Look at ways to ensure adoption of most impactful standards Meetings are the 4th Monday of the month at 3p Eastern.
Member only content

Home Testing

1st Mondays, 3 pm EDT
78 Members
Last Activity: September 22, 2022
Broad access to home testing can expand the spectrum of ways telehealth can be used, and likewise, leveraging telehealth to supervise sample collection at home and interpretation of results could expand the potential of tests that can be effectively done outside of a clinic or healthcare facility. But lab test availability in the home has been limited and lab tests are not generally available for telehealth encounters. While the COVID-19 pandemic has greatly accelerated the market availability of over-the-counter home sample collection and home testing solutions, either with or without a prescription, adoption has been relatively modest. The Home Testing SIG brings together medical, scientific, technology solution, laboratory and regulatory experts to address barriers to adoption and to accelerate use of home testing as a part of virtual care. Some of the questions we’ll be addressing: What are the barriers? Does a lack of a common industry language around home testing slow down adoption? Do the lack of specific performance requirements contribute to a lack of clarity in regulation and limited reimbursement? What can industry do to help accelerate home testing adoption by better connection to telehealth solutions? All players with a role in the remote testing ecosystem are encouraged to join the ATA and its new Home Testing SIG to define an industry vision, identify the barriers and collaborate in catalyzing industry action to accelerate adoption of home testing with and for telehealth.